Health

Biogen’s Alzheimer’s Drug Slows Mental Decline in Early Study

Two women walk by Biogen Idec corporate headquarters in Cambridge, Mass. in this Feb. 15, 2006 file photo. (Elise Amendola/AP File)
Two women walk by Biogen Idec corporate headquarters in Cambridge, Mass. in this Feb. 15, 2006 file photo. (Elise Amendola/AP File)

 

(Reuters) – An experimental drug from Biogen Idec Inc became the first Alzheimer’s treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment.

Alzheimer’s affects 15 million people worldwide, a number that is expected to grow to 75 million by 2030 without effective treatments, likely costing billions of dollars year.

Any effective treatment is likely to become one of the world’s most lucrative drugs, but the Biogen drug faces years of testing and would not reach the market much before 2020, even if all goes well, analysts said.

Biogen shares were up 6.5 percent, or $27.97, at $461.92 in morning trading, after rising as high as $480.18.

Biogen is entering a field littered with expensive failures from such drug makers as Pfizer Inc and Eli Lilly and Co. Lilly and Roche Holding AG are both conducting trials on drugs that work the same way as Biogen’s, by blocking beta amyloid, a protein that forms toxic brain plaques that are theoretically an underlying cause of the degenerative brain disease.

READ MORE

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker